GlobeNewswire

Lyell Immunopharma To Participate in November Investor Events
02/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell [...]
Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response
02/11/2026
In patients aged 64+: 79.2% of patients achieved a clinically meaningful response (reduced pain and improved knee function) in the Allocetra™ group vs. 47.6% in the placebo group at 12 months (p=0.027) 1 Allocetra™ [...]
Rein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
02/11/2026
AUSTIN, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications [...]
Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.
02/11/2026
– Theriva received a $350,000 upfront payment at closing and is eligible for up to $91 million in regulatory and sales milestones, along with low single-digit royalties on net product sales – – Biossil to assume all [...]
Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026
02/11/2026
DURHAM, N.C, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
Eyconis to Participate in Upcoming Investor Conferences
02/11/2026
REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a clinical-stage biotechnology company advancing next-generation, long-acting ophthalmic therapeutics, today announced that members of its [...]
New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
02/11/2026
MONTREAL and CHARLOTTE, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
02/11/2026
ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately [...]
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
02/11/2026
FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of [...]
CytomX Therapeutics to Present at Upcoming November Investor Conferences
02/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will [...]
Alfasigma Announces New Linerixibat Data Across PBC and Liver Disease to be Presented at AASLD’s The Liver Meeting 2026
02/11/2026
Five presentations will highlight new analyses of linerixibat in cholestatic pruritus associated with primary biliary cholangitis, including an oral presentation and four posters from the Phase 3 GLISTEN study and real- [...]
Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data
02/11/2026
WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease
02/11/2026
~ FDA sets PDUFA target action date of May 1, 2027 ~ ~ If approved, ifezuntirgene inilparvovec will be the world’s first disease-modifying treatment for Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 02, [...]
Kraig Biocraft Laboratories Takes Spider Silk Optimization Beyond Genetics with New Dietary Additive Program
02/11/2026
Program Adds Targeted Nutrition to Genetic Engineering to Fuel Spider Silk Proteins ANN ARBOR, Mich., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or " [...]
Alvotech to Present at Upcoming Investor Conferences in November
02/11/2026
REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced [...]
Alvotech to Present at Upcoming Investor Conferences in November
02/11/2026
REYKJAVIK, Iceland, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
02/11/2026
Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY ® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI ® 3Q 2026 net product [...]
Vireo Growth to Report Third Quarter 2026 Financial Results on November 10, 2026
02/11/2026
MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced that the Company will host a conference call on Tuesday, November 10, 2026, at 8:00 [...]
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026
02/11/2026
Company to Host Conference Call at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum